Canadian Population Serological Survey Utilizing Antenatal Serum Samples
The objectives of the Canadian Population Serological Survey Utilizing Antenatal Serum Samples are to:
* Provide an immediate cross-sectional assessment of the seroprevalence of antibodies to SARS-CoV-2 in Canada.
* Assess the retrospective evolution of SARS-CoV-2 prevalence; antenatal serology can be assessed going back one year thereby providing an opportunity to go back to where 0% prevalence is detected.
* Plan to perform periodic future seroprevalence based on the level of seroprevalence on the first cross-sectional assessment.
* Compare seroprevalence between Canadian provinces and territories.
Overview
- Acronym
- CPSS-Antenatal
- Website
- CPSS-Antenatal
- Investigators
-
- Contacts
-
General Design
- Study design
- Cross-sectional
- Start - End Year
- 2020 - 2021
- General Information on Follow Up (profile, frequency)
-
Periodic assessment of seroprevalence of SARS-CoV-2 utilizing clinically collected prenatal serology samples may be planned for future time points. The frequency and number of samples will be determined based on findings from the first cross-sectional assessment.
- Recruitment Target
-
- Individuals
- Number of Participants
- 18,000
- Supplementary information about number of participants
-
Cohort 1: 18,000 participants
Access
Availability of data and biosamples
| Possible Access to Data | |
| Possible Access to Biosamples | |
| Other |
|
Timeline
Populations
CPSS-Antenatal - Cohort 1
The population is composed of pregnant women in all provinces and territories of Canada who have their prenatal serology results available in laboratories.
Selection Criteria
- Gender
-
Women only
- Pregnant Women
-
- First trimester
- Countries
-
- Canada
- Territory
- British Columbia, Yukon, Alberta, Northwest Territories, Saskatchewan, Manitoba, Ontario, Quebec, Newfoundland, New Brunswick, Nova Scotia, Prince Edward Island, Nunavut
- Other Criteria
- Had a routine blood screening of the antibody status to rubella, HIV, Hepatits B and syphilis
Sources of Recruitment
- Specific Population
-
- Clinic patients
- Supplementary Information
-
Pregnant women who get a routine blood screening for prenatal care and who have their serological test results available for testing.
Sample Size
- Number of Participants
- 18,000
- Number of Participants with Biological Samples
- 18,000
Data Collection Events
| # | Name | Description | Start | End |
|---|---|---|---|---|
| 0 | CPSS-Antenatal - Cohort 1 - Serotest | Collected blood samples for prenatal serological survey were sequestered in November ... | 2020 (November) | 2021 (March) |
CPSS-Antenatal - Cohort 2
The population is composed of pregnant women in all provinces and territories of Canada who have their antenatal screening for aneuploidy results available in laboratories.
Selection Criteria
- Gender
-
Women only
- Pregnant Women
-
- First trimester
- Second trimester
- Countries
-
- Canada
- Territory
- British Columbia, Yukon, Alberta, Northwest Territories, Saskatchewan, Manitoba, Ontario, Quebec, Newfoundland, New Brunswick, Nova Scotia, Prince Edward Island, Nunavut
- Other Criteria
- Had an aneuploidy blood screening
Sources of Recruitment
- Specific Population
-
- Clinic patients
- Supplementary Information
-
Pregnant women who get a routine blood screening for prenatal care and who have their aneuploidy test results data available for testing.
Data Collection Events
| # | Name | Description | Start | End |
|---|---|---|---|---|
| 0 | CPSS-Antenatal - Cohort 2 - Retrospective survey | A retrospective assessment of seroprevalence using blood samples from aneuploidy blood ... | 2019 (December) | 2020 (December) |
Participating Studies
| Acronym | Name | Study design | Countries |
|---|
Harmonization Initiatives Included
| Acronym | Name |
|---|
Networks
| Acronym | Name | Harmonization Initiatives | Individual Studies |
|---|
Datasets
| Name | Type | Data Collection Events | Variables |
|---|
Last Update: 2022-04-04 21:06